{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T02:58:27Z","timestamp":1789441107229,"version":"build-2803163510"},"reference-count":18,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T00:00:00Z","timestamp":1737504000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004470","name":"Daewoong Pharmaceutical Company","doi-asserted-by":"publisher","award":["KHU-20222720"],"award-info":[{"award-number":["KHU-20222720"]}],"id":[{"id":"10.13039\/501100004470","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>Sodium-glucose co-transporter 2 inhibitors, such as enavogliflozin, offer promising metabolic benefits for patients with type 2 diabetes (T2D), including glycemic control and improved cardiac function. Despite the clinical evidence, real-world evidence is needed to validate their safety and effectiveness. This study aims to evaluate the effects of weight loss and safety of enavogliflozin administration in patients with T2D in a real-world clinical setting over 24 weeks. This is a large-scale, prospective, multicenter, non-interventional observational study and will be conducted in 12 primary care centers nationwide between 2024 and 2026. Data will be collected at baseline, 12 weeks, and 24 weeks in a real-world clinical setting, including demographic details, clinical history, lifestyle habits, medication use, and various health indicators. Eligible participants are adults aged 19 to 80 with T2D and a body mass index (BMI) of \u226523\u2009kg\/m<jats:sup>2<\/jats:sup> who are currently receiving treatment with Envlo (enavogliflozin) or Envlomet (enavogliflozin\/metformin) tablets or planning to start treatment. The primary outcome is the change in BMI and body weight at 24 weeks from baseline. Secondary outcomes evaluated are changes in BMI and weight at 12 weeks, the proportion of participants achieving significant reductions in BMI and weight at 12 and 24 weeks, and body composition and glycemic improvements at 12 and 24 weeks. The study will analyze shifts in lipid profiles, liver and kidney functions, and body composition at 12 and 24 weeks as exploratory outcomes. For safety outcomes, the trial will prioritize the monitoring of adverse drug reactions and specific events of interest such as hypoglycemia, urinary tract infections, genital infections, polyuria, and polydipsia. This study design enables us to evaluate the effectiveness and safety of enavogliflozin for weight loss in a real-world setting while exploring its potential positive effects on cardiac function and metabolic risk factors in overweight or obese patients with T2D.<\/jats:p>","DOI":"10.1371\/journal.pone.0315603","type":"journal-article","created":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T18:40:04Z","timestamp":1737571204000},"page":"e0315603","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":1,"title":["An anonymized, de-identified registry study protocol to determine the effectiveness and safety of weight loss with enavogliflozin in patients with type 2 diabetes mellitus"],"prefix":"10.1371","volume":"20","author":[{"given":"Hyunji","family":"Sang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunyoung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiyoung","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selin","family":"Woo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1365-3089","authenticated-orcid":true,"given":"Jaewon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong Keon","family":"Yon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0119-5818","authenticated-orcid":true,"given":"Sang Youl","family":"Rhee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2025,1,22]]},"reference":[{"issue":"3","key":"pone.0315603.ref001","doi-asserted-by":"crossref","first-page":"417","DOI":"10.4093\/dmj.2022.0106","article-title":"Diabetes fact sheet in Korea 2021","volume":"46","author":"JH Bae","year":"2022","journal-title":"Diabetes Metab J"},{"issue":"2","key":"pone.0315603.ref002","doi-asserted-by":"crossref","first-page":"335","DOI":"10.4143\/crt.2020.206","article-title":"Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2017","volume":"52","author":"S Hong","year":"2020","journal-title":"Cancer Res Treat"},{"issue":"3","key":"pone.0315603.ref003","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/S2213-8587(20)30003-6","article-title":"Time-varying risk of microvascular complications in latent autoimmune diabetes of adulthood compared with type 2 diabetes in adults: a post-hoc analysis of the UK prospective diabetes study 30-year follow-up data (UKPDS 86)","volume":"8","author":"E Maddaloni","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"10","key":"pone.0315603.ref004","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1177\/2047487317702041","article-title":"Diabetes control: incidence of acute myocardial infarction and all-cause mortality among patients with 3\u20136 years\u2019 disease duration","volume":"24","author":"O Reges","year":"2017","journal-title":"Eur J Prev Cardiol"},{"issue":"5","key":"pone.0315603.ref005","doi-asserted-by":"crossref","first-page":"575","DOI":"10.4093\/dmj.2023.0282","article-title":"Clinical practice guidelines for diabetes mellitus of the Korean diabetes association","volume":"47","author":"JH Choi","year":"2023","journal-title":"Diabetes Metab J"},{"issue":"3","key":"pone.0315603.ref006","doi-asserted-by":"crossref","first-page":"e005066","DOI":"10.1161\/JAHA.116.005066","article-title":"Ketone body infusion with 3-hydroxybutyrate reduces myocardial glucose uptake and increases blood flow in humans: a positron emission tomography study","volume":"6","author":"LC Gormsen","year":"2017","journal-title":"J Am Heart Assoc"},{"issue":"2","key":"pone.0315603.ref007","doi-asserted-by":"crossref","first-page":"47","DOI":"10.22730\/jmls.2020.17.2.47","article-title":"The relationship between glucagon levels and cardiovascular risk in patients with type 2 diabetes","volume":"17","author":"W Jeong","year":"2020","journal-title":"J Med Life Sci"},{"issue":"8","key":"pone.0315603.ref008","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1111\/dom.15080","article-title":"Efficacy and safety of monotherapy with enavogliflozin in Korean patients with type 2 diabetes mellitus: results of a 12-week, multicentre, randomized, double-blind, placebo-controlled, phase 2 trial","volume":"25","author":"YS Yang","year":"2023","journal-title":"Diabetes Obes Metab"},{"issue":"9","key":"pone.0315603.ref009","doi-asserted-by":"crossref","first-page":"4100","DOI":"10.1111\/bcp.15348","article-title":"Dose-dependent glucosuria of DWP16001, a novel selective sodium-glucose cotransporter-2 inhibitor, in healthy subjects","volume":"88","author":"JG Hwang","year":"2022","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"pone.0315603.ref010","doi-asserted-by":"crossref","first-page":"200","DOI":"10.7326\/0003-4819-158-3-201302050-00583","article-title":"SPIRIT 2013 statement: defining standard protocol items for clinical trials","volume":"158","author":"AW Chan","year":"2013","journal-title":"Ann Intern Med"},{"issue":"2","key":"pone.0315603.ref011","doi-asserted-by":"crossref","first-page":"121","DOI":"10.7570\/jomes23031","article-title":"Diagnosis of obesity: 2022 update of clinical practice guidelines for obesity by the Korean society for the study of obesity","volume":"32","author":"JH Haam","year":"2023","journal-title":"J Obes Metab Syndr"},{"key":"pone.0315603.ref012","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3352\/jeehp.2021.18.17","article-title":"Sample size determination and power analysis using the G*Power software","volume":"18","author":"H Kang","year":"2021","journal-title":"J Educ Eval Health Prof"},{"issue":"4","key":"pone.0315603.ref013","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.jada.2009.12.026","article-title":"Alcoholic beverage consumption, nutrient intakes, and diet quality in the US adult population, 1999\u20132006","volume":"110","author":"RA Breslow","year":"2010","journal-title":"J Am Diet Assoc"},{"issue":"1","key":"pone.0315603.ref014","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1186\/s12889-023-17155-9","article-title":"Association between having a meal together with family and smoking: a cross-sectional nationwide survey","volume":"23","author":"GH Cho","year":"2023","journal-title":"BMC Public Health"},{"issue":"1","key":"pone.0315603.ref015","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.diabet.2015.10.001","article-title":"Fasting hyperinsulinaemia and 2-h glycaemia predict coronary heart disease in patients with type 2 diabetes","volume":"42","author":"S Faghihi-Kashani","year":"2016","journal-title":"Diabetes Metab"},{"key":"pone.0315603.ref016","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.54724\/lc.2022.e1","article-title":"Methods for testing statistical differences between groups in medical research: statistical standard and guideline of Life Cycle committee","volume":"2","author":"SW Lee","year":"2022","journal-title":"Life Cycle"},{"issue":"1","key":"pone.0315603.ref017","first-page":"1","article-title":"Regression analysis for continuous independent variables in medical research: statistical standard and guideline of Life Cycle committee","volume":"10","author":"SW Lee","year":"2023","journal-title":"J Life Cycle"},{"key":"pone.0315603.ref018","article-title":"Efficacy and safety of topical Streptococcus postbiotic emollient in adolescents and adults with mild-to-moderate atopic dermatitis: a randomized, double-blind, vehicle-controlled trial","author":"MS Kim","year":"2024","journal-title":"Allergy"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0315603","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T18:40:10Z","timestamp":1737571210000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0315603"}},"subtitle":[],"editor":[{"given":"Aleksandra","family":"Klisic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,1,22]]},"references-count":18,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1,22]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0315603","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,22]]}}}